“…Indeed, different classes of sulfonamides and related compounds can efficiently inhibit CA IX. In addition to classical sufonamides, such as acetazolamide (AZM), methazolamide, ethoxzolamide, and dichlorophenamide, good-to-excellent CA IX inhibitory properties were proven for aromatic and heterocyclic sulfonamides Jaiswal et al 2004;Ozensoy et al 2005), halogenosulfanilamide and halogenophenylaminobenzolamide derivatives (Ilies et al 2003), lipophilic sulfonamides , sulfamates (Winum et al 2003a), aliphatic sulfamates (Winum et al 2003b), fluorine-containing sulfonamides , sulfonamides incorporating 1,3,5-triazine and 1,2,4-triazine moieties (Garaj et al 2004(Garaj et al , 2005, sulfonamides derived from 4-isothiocyanato-benzolamide (Cecchi et al 2004), E7070 sulfonamide developed originally as an anticancer agent blocking the cell cycle (Abbate et al 2004), sulfonamides incorporating thioureido-sulfanilyl scaffolds , novel sulfanilamide/AZM derivatives obtained by the tail approach (Turkmen et al 2005), bis-sulfamates (Winum et al 2005a), sulfonamides incorporating hydrazine moieties (Winum et al 2005b), 1,3,4-thiadiazole-and 1,2,4-triazole-thiols (Almajan et al 2005), N-hydroxysulfamides (Winum et al 2005c), polyfluorinated aromatic/heterocyclic sulfonamides , benzo[b]thiophene 1,1 dioxide sulfonamides , substituted difluoromethanesulfonamides , indanesulfonamides (Thiry et al 2006), and copper(II) complexes of polyamino-polycarboxylamido aromatic/heterocyclic sulfonamides (Rami et al 2008). Interestingly, CA IX can be also efficiently inhibited by nanomolar concentrations of celecoxib and valdecoxib sulfonamide inhibitors of cyclooxygenase 2 (COX-2), which is a key enzyme of arachidonic acid metabolism involved in colorectal carcinoma (Weber et al 2004;Dogne et al 2007).…”